Solid Biosciences (SLDB) Long-Term Debt Repayments (2024 - 2025)
Solid Biosciences (SLDB) posted Long-Term Debt Repayments of $203000.0 for Q4 2025, down 16.46% sequentially from $243000.0 in Q3 2025, and up 58.59% YoY from $128000.0 in Q4 2024.
Powered by 
Analysis
Solid Biosciences (SLDB) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends
Solid Biosciences has reported Long-Term Debt Repayments for 2 years, with the latest figure at $203000.0 in Q4 2025.
- Quarterly Long-Term Debt Repayments rose 58.59% year-over-year to $203000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $588000.0 (down 3.29% YoY) and the FY2025 annual result came in at $723000.0, up 52.85% from the prior year.
- Long-Term Debt Repayments eased to $203000.0 in Q4 2025 per SLDB's latest filing, from $243000.0 in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $243000.0 in Q3 2025 and troughed at $120000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 203,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 225,000.00 |